Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 8th:Akoya Biosciences, Inc. (AKYA) : This life-sciences technology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 10.4% over the last 60 days.Akoya’s shares gained 11.9% over the last three months compared with the S&P 500’s advance of 8%. The company possesses a Momentum Score  of A.Alpha Tau Medical Ltd. (DRTS) : This clinical-sta ...

MaxFuse enables matching and integration of datasets from spatial proteomics, spatial transcriptomics, single-cell sequencing, or other modalities Development and application of MaxFuse were described in two recent Nature publications MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, in collaboration with Enable Medicine, a leading provider of AI-powered biological insights, announces the availability of MaxFuse, an advanced algorithm ...

Financial Data and Key Metrics Changes - Akoya reported record revenue of $25.2 million for Q3 2023, reflecting a 34% increase year-over-year [7][19] - Gross profit reached $15.3 million, a 40% growth compared to the prior year, with a gross margin of 60.6% [7][22] - Operating expenses decreased to $26.8 million from $27.6 million in the prior year, indicating a focus on cost management [23] Business Line Data and Key Metrics Changes - Product revenue, including instruments, reagents, and software, totaled $18 million, representing a 25% increase year-over-year [19] - Instrument revenue was $12 million, showing a 27% growth, with 69 instruments sold during the quarter [19][20] - Reagent revenue reached $5.7 million, reflecting a 21% increase, with annualized reagent pull-through now in the mid $30,000 range [21] Market Data and Key Metrics Changes - The Americas market grew in the mid-40% range year-over-year, while EMEA saw mid-20% growth; APAC experienced mid-single-digit growth [42] - The installed base of instruments reached 1,132, solidifying Akoya's position as a leader in spatial biology [24] Company Strategy and Development Direction - Akoya is focused on enhancing applications and workflow efficiency through the Spatial Biology 2.0 initiative, which includes system improvements and expanded PhenoCode offerings [17] - The company aims to drive clinical adoption and operational excellence while targeting cash flow positivity by 2025 [18][25] - Strategic investments are being made to maintain operating expenses while scaling the business [8][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining strong growth throughout 2023 and beyond, reaffirming revenue guidance of $95 million to $98 million for the year [25] - The company is optimistic about the clinical opportunities arising from partnerships and the growing demand for spatial biology solutions [82] Other Important Information - Akoya's installed base includes 327 PhenoCyclers and 805 PhenoImagers, with expectations for significant upgrades to the 2.0 versions by year-end [20] - The company has established partnerships with leading software providers to enhance data analysis capabilities [14] Q&A Session Summary Question: Update on the 2.0 rollout progress - Management expects about 50% of both platforms to be upgraded by year-end, with no significant changes to previous expectations [29][31] Question: Insights on gross margin improvement - Gross margin is expected to improve through supply chain efficiencies and a shift towards higher-margin reagent sales [38][40] Question: Market demand and capital purchases - There is a slight lengthening in visibility around capital purchases, but the affordability of Akoya's platforms is seen as a competitive advantage [44][45] Question: Growth outlook for services business - Continued growth is anticipated in the services segment driven by an expanding installed base and partnerships with CROs [75] Question: Adoption of PhenoCode Panels - The timeline for higher utilization of PhenoCode Panels is expected to align with the rollout of system upgrades and increased CRO engagement in 2024 [79]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-40344 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) ...

Akoya Biosciences, Inc. (NASDAQ:AKYA) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Priyam Shah - Head of Investor Relations Brian McKelligon - Chief Executive Officer Johnny Ek - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Lucas Baranowski - UBS Rachel Vatnsdal - JPMorgan Chase Mark Massaro - BTIG Edmund Tu - Morgan Stanley Tim Chiang - Capital One David Westenberg - Piper Sandler Mason Carrico - Stephens Inc. Operator Good day and ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-40344 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) D ...

Akoya Biosciences, Inc. (NASDAQ:AKYA) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Priyam Shah - Investor Relations Brian McKelligon - Chief Executive Officer John Ek - Chief Financial Officer Conference Call Participants Tim Chiang - Capital One Mason Carrico - Stephens Inc Ruizhi Qin - JPMorgan Vivian Bais - BTIG Kyle Mikson - Canaccord Genuity David Westenberg - Piper Sandler Lucas Baranowski - UBS Operator Good day and thank you for standing by. Welcome to the Akoya Biosc ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-40344 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) ...

Financial Data and Key Metrics Changes - Akoya reported record revenue of $21.2 million in Q4 2022, representing a 31% growth over Q4 2021, and full-year revenue of $74.9 million, a 36% increase over the previous year [22][30] - Gross profit for Q4 was $12 million, with a full-year gross margin of 58% [27] - Operating expenses totaled $29.6 million for Q4 and $109.5 million for the full year, reflecting significant investments in business expansion [28] Business Line Data and Key Metrics Changes - Product revenue, including instruments, reagents, and software, was $15.7 million for Q4 and $57.7 million for the full year, marking a 30% growth year-over-year [22] - Instrument revenue was $11.1 million for Q4 and $38.6 million for the full year, representing a 35% increase year-over-year [23] - Reagent revenue was $4.5 million for Q4 and $18.4 million for the full year, showing a 29% growth over the previous year [24] Market Data and Key Metrics Changes - The installed base of instruments reached 934 by the end of 2022, with 71 instruments sold in Q4 and 237 for the full year, a 61% growth in placements from the prior year [8][30] - The company has the largest installed base of spatial instruments in the industry, with a target to reach 1,000 instruments early in 2023 [8] Company Strategy and Development Direction - Akoya aims to enhance its leadership in spatial biology by introducing platform and workflow improvements across its instrument line, focusing on operational efficiencies and targeted investments in 2023 [10][20] - The company plans to expand its product offerings with the launch of PhenoCode panels and improvements to existing systems, which are expected to drive reagent pull-through and increase revenue [11][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of the spatial biology market, citing strong commercial execution and a growing installed base as key drivers for future performance [8][20] - The company provided preliminary revenue guidance for 2023 in the range of $95 million to $98 million, anticipating continued growth despite macroeconomic challenges [31] Other Important Information - Akoya's Advanced BioPharma Solutions CLIA Lab is gaining traction with large pharma partners, contributing to service revenue growth [26] - The company is focused on partnerships with leading biopharma and diagnostic leaders to drive the adoption of its products in clinical diagnostics [20] Q&A Session Summary Question: Can you provide insights on the 2023 guidance regarding instrument pull-through and consumable mix? - Management indicated that while many customers are not yet at full utilization of the PhenoCycler Fusion, they expect gradual increases in pull-through as more customers become fully operational [33][35] Question: What is the current cash position and any potential financing plans? - The company reported $81 million in cash and $11 million in additional debt capacity, indicating a solid cash position for continued growth [36][37] Question: What factors contributed to the reagent revenue performance in Q4? - Management noted that COVID lockdowns in China and currency issues in Europe impacted reagent revenue, but order volumes have picked up in Q1 2023 [51][53] Question: How is the company addressing the elongation of capital purchase timelines? - Management acknowledged some elongation in capital purchase timelines, particularly in EMEA, but did not anticipate a material impact on overall performance [55][57] Question: What is the expected contribution of new products to the 2023 revenue guidance? - Management indicated that while new products like the PhenoCode panels will contribute, the overall impact is modest, with a focus on driving reagent revenue growth through existing products [70][74]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-40344 (Address of principal executive offices) (Zip Code) (855) 896-8401 Registrant's tele ...